Streptococcus pyogenes Cas9 ribonucleoprotein delivery for efficient, rapid and marker‐free gene editing in Trypanosoma and Leishmania
Molecular Microbiology · 2024
DOI: 10.1111/mmi.15256 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Microbiology, 2024. Verfasst von Corinne Asencio und 13 weiteren Autor:innen. Beteiligte Einrichtung: Univ. Bordeaux, CNRS, MFP, UMR 5234, Bordeaux, France. Hauptthemen laut MEDLINE: Gene Editing, CRISPR-Cas Systems, Ribonucleoproteins. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Fondation pour la Recherche Médicale, IDEX.
Abstract (Originalsprache)
Kinetoplastids are unicellular eukaryotic flagellated parasites found in a wide range of hosts within the animal and plant kingdoms. They are known to be responsible in humans for African sleeping sickness ( Trypanosoma brucei ), Chagas disease ( Trypanosoma cruzi ), and various forms of leishmaniasis ( Leishmania spp.), as well as several animal diseases with important economic impact (African trypanosomes, including Trypanosoma congolense ). Understanding the biology of these parasites necessarily implies the ability to manipulate their genomes. In this study, we demonstrate that transfection of a ribonucleoprotein complex, composed of recombinant Streptococcus pyogenes Cas9 ( Sp Cas9) and an in vitro‐synthesized guide RNA, results in rapid and efficient genetic modifications of trypanosomatids, in marker‐free conditions. This approach was successfully developed to inactivate, delete, and mutate candidate genes in various stages of the life cycle of T. brucei and T. congolense , and Leishmania promastigotes. The functionality of Sp Cas9 in these parasites now provides, to the research community working on these parasites, a rapid and efficient method of genome editing, without requiring plasmid construction and selection by antibiotics but requires only cloning and PCR screening of the clones. Importantly, this approach is adaptable to any wild‐type parasite.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Univ. Bordeaux, CNRS, MFP, UMR 5234, Bordeaux, France.
- Univ. Bordeaux, CNRS/INSERM, TBMCore/CRISP'edit, UAR 3427/US005, Bordeaux, France.
- Univ. Bordeaux, CNRS, CRMSB, UMR 5536, Bordeaux, France.
- Centre de Recherche en Infectiologie du Centre de Recherche du CHU de Québec, Département de Microbiologie, Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Québec, Québec, Canada.
ORCID-Profile: Emmanuel Tetaud
Förderung
- CIHR
- Fondation pour la Recherche Médicale
- IDEX
- Centre National de la Recherche Scientifique
- Université de Bordeaux
- Agence Nationale de la Recherche
- Canadian Institutes of Health Research
Zitieren
APA
Asencio, C., Hervé, P., Morand, P., Oliveres, Q., Morel, C. A., Prouzet-Mauleon, V., Biran, M., Monic, S., Bonhivers, M., Robinson, D. R., Ouellette, M., Rivière, L., Bringaud, F., & Tetaud, E. (2024). Streptococcus pyogenes Cas9 ribonucleoprotein delivery for efficient, rapid and marker‐free gene editing in Trypanosoma and Leishmania. Molecular Microbiology. https://doi.org/10.1111/mmi.15256
Vancouver
Asencio C, Hervé P, Morand P, Oliveres Q, Morel CA, Prouzet-Mauleon V, et al. Streptococcus pyogenes Cas9 ribonucleoprotein delivery for efficient, rapid and marker‐free gene editing in Trypanosoma and Leishmania. Molecular Microbiology. 2024. doi:10.1111/mmi.15256
BibTeX
@article{Asencio2024,
author = {Asencio, Corinne and Hervé, Perrine and Morand, Pauline and Oliveres, Quentin and Morel, Chloé Alexandra and Prouzet-Mauleon, Valérie and Biran, Marc and Monic, Sarah and Bonhivers, Mélanie and Robinson, Derrick Roy and Ouellette, Marc and Rivière, Loïc and Bringaud, Frédéric and Tetaud, Emmanuel},
title = {Streptococcus pyogenes Cas9 ribonucleoprotein delivery for efficient, rapid and marker‐free gene editing in Trypanosoma and Leishmania},
journal = {Molecular Microbiology},
year = {2024},
doi = {10.1111/mmi.15256}
}
EUVIMED